Company Filing History:
Years Active: 1997-2004
Title: The Innovations of Jean-Pierre Szikora
Introduction
Jean-Pierre Szikora is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of 2 patents, Szikora's work focuses on identifying and treating individuals suffering from cellular abnormalities.
Latest Patents
One of his latest patents is titled "Method for Identifying Individuals Suffering from a Cellular Abnormality Some of Whose Abnormal Cells Present Complexes of HLA-CW 1601/MAGE-1 Derived Peptides." This invention involves peptides that bind to HLA-Cw*1601 molecules and stimulate the proliferation of cytolytic T cells. Examples of such peptides are detailed in SEQ ID NOS: 4 and 5. Another significant patent relates to isolated nucleic acid molecules that are useful in determining the expression of the MAGE tumor rejection antigen precursors. These nucleic acid molecules serve as diagnostic aids for identifying whether an individual has cancer, and methods utilizing these molecules are also described.
Career Highlights
Jean-Pierre Szikora is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research and innovations. His work has the potential to impact cancer diagnostics and treatment significantly.
Collaborations
Szikora has collaborated with notable colleagues such as Thierry R Boon-Falleur and Etienne De Plaen, contributing to the advancement of cancer research through shared expertise and innovative ideas.
Conclusion
Jean-Pierre Szikora's contributions to cancer research through his patents highlight his role as a significant inventor in the field. His innovative methods for identifying and treating cellular abnormalities demonstrate the potential for improving cancer diagnostics and therapies.